Generic Medicine Info
Indications and Dosage
Allergic conditions
Adult: 4 mg 4-6 hrly.
Child: 2-6 yr 1 mg 4-6 hrly; >6-12 yr 2 mg 4-6 hrly; >12 yr Same as adult dose.
May be taken with or without food. May be taken w/ food or milk to reduce GI discomfort.
Incompatible w/ some amidotrizoate, adipiodone and iotalamate salts.
Pregnancy (3rd trimester).
Special Precautions
Patient w/ glaucoma, prostatic hyperplasia, genitourinary obstruction, asthma, chronic bronchitis, thyroid dysfunction, CV disease (e.g. HTN, ischaemic heart disease). Childn. Pregnancy and lactation.
Adverse Reactions
Excitability (esp in childn), drowsiness, sedation, angina pectoris, chest tightness, circulatory shock, extrasystoles, hypotension, palpitation, increased BP, tachycardia, anxiety, ataxia, chills, confusion, euphoria, fatigue, headache, hysteria, insomnia, irritability, nervousness, neuritis, paraesthesia, restlessness, seizure, tension, vertigo, diaphoresis, photosensitivity, rash, urticaria, abdominal cramps, anorexia, constipation, diarrhoea, epigastric distress, heartburn, nausea, vomiting, xerostomia, dysuria, early menstruation, urinary retention, agranulocytosis, haemolytic anaemia, thrombocytopenia, tremor, weakness, diplopia, mydriasis, blurred vision, acute labyrinthitis, tinnitus, polyuria, dry nose or throat, nasal congestion, bronchial secretions, wheezing.
Patient Counseling Information
This drug may cause drowsiness and sedation, if affected, do not drive or operate machinery.
Drug Interactions
May enhance the sedative effects of CNS depressants (e.g. barbiturates, anxiolytics, hypnotics, opioid analgesics, antipsychotics). Additive antimuscarinic effects w/ other antimuscarinic drugs (e.g. atropine, TCAs, MAOIs). May mask the warning signs of damage caused by ototoxic drugs (e.g. aminoglycosides).
Food Interaction
May enhance the CNS depressant effects of alcohol.
Lab Interference
May cause false-positive result w/ urine detection of amphetamine/methamphetamine. May interfere w/ skin tests using allergen extracts.
Mechanism of Action: Brompheniramine is an antihistamine w/ antimuscarinic and moderate sedative actions. It competes w/ histamine for H1-receptor sites on effector cells.
Absorption: Well absorbed from the GI tract. Time to peak plasma concentration: 2-4 hr.
Distribution: Widely distributed. Volume of distribution: Approx 12 L/kg. Plasma protein binding: 39-49%.
Metabolism: Undergoes N-dealkylation to form monodesmethylbrompheniramine and didesmethylbrompheniramine, and is metabolised to propionic acid derivative.
Excretion: Via urine (approx 40%, as unchanged drug and metabolites) and faeces (approx 2%). Elimination half-life: Approx 25 hr.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Brompheniramine, CID=6834, (accessed on Jan. 22, 2020)

Store between 15-30°C. Protect from light.
MIMS Class
Antihistamines & Antiallergics
ATC Classification
R06AB01 - brompheniramine ; Belongs to the class of substituted alkylamines used as systemic antihistamines.
Anon. Brompheniramine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 23/08/2016.

Buckingham R (ed). Brompheniramine maleate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 23/08/2016.

Buckingham R (ed). Interactions of Antihistamines . Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 23/09/2016 .

J-TAN PD Liquid (JayMac Pharmaceuticals LLC). DailyMed. Source: U.S. National Library of Medicine. Accessed 23/08/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Brompheniramine Maleate, Dexbrompheniramine Maleate . AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 23/08/2016.

Disclaimer: This information is independently developed by MIMS based on Brompheniramine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
  • Bomex
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in